61 Grants (Page 1 of 3)
2021
Exploiting the immunomodulatory effects of sulindac and novel non-COX inhibitory derivatives for cancer treatment
PIAZZA, GARY A and ZHOU, GANG
National Institutes of Health (NIH), National Cancer Institute (NCI) (ID: 5R01CA238514-02), $431,691USD, 2020-03-01 -- 2025-02-28
 
Novel inhibitor for oncogenic RAS for lung cancer
PIAZZA, GARY A
National Institutes of Health (NIH), National Cancer Institute (NCI) (ID: 1R01CA254197-01A1), $394,585USD, 2021-03-01 -- 2026-02-28
 
Novel inhibitor for oncogenic RAS for lung cancer
PIAZZA, GARY
National Institutes of Health (NIH), National Cancer Institute (NCI) (ID: 7R01CA254197-02), $394,586USD, 2021-03-01 -- 2026-06-30
2020
Exploiting the immunomodulatory effects of sulindac and novel non-COX inhibitory derivatives for cancer treatment
PIAZZA, GARY A and ZHOU, GANG
National Institutes of Health (NIH), National Cancer Institute (NCI) (ID: 1R01CA238514-01A1), $444,328USD, 2020-03-01 -- 2025-02-28
 
Phosphodiesterase 10A, a novel target for lung cancer chemoprevention
PIAZZA, GARY A
National Institutes of Health (NIH), National Cancer Institute (NCI) (ID: 5R01CA197147-05), $434,772USD, 2016-07-15 -- 2021-06-30
 
Phosphodiesterase 10A, a novel target for lung cancer chemoprevention
PIAZZA, GARY A
National Institutes of Health (NIH), National Cancer Institute (NCI) (ID: 7R01CA197147-06), $267,424USD, 2021-07-23 -- 2022-06-30
2019
Enhancing the Immune System by Targeting the RAS Signaling Pathway in Cancer: Immunotherapeutic Potential of a Novel RAS Inhibitor for lung cancer treatment.
PIAZZA, GARY A
National Institutes of Health (NIH), National Cancer Institute (NCI) (ID: 3R01CA197147-04S1), $81,635USD, 07/15/2016 -- 06/30/2021
 
Novel Sulindac Derivatives for Colon Cancer Chemoprevention
PIAZZA, GARY A
National Institutes of Health (NIH), National Cancer Institute (NCI) (ID: 5R01CA131378-11), $365,641USD, 01/01/2008 -- 05/31/2020
 
Phosphodiesterase 10A, a novel target for lung cancer chemoprevention
PIAZZA, GARY A
National Institutes of Health (NIH), National Cancer Institute (NCI) (ID: 5R01CA197147-04), $336,158USD, 07/15/2016 -- 06/30/2021
2018
Novel Sulindac Derivatives for Colon Cancer Chemoprevention
PIAZZA, GARY A
National Institutes of Health (NIH), National Cancer Institute (NCI) (ID: 5R01CA131378-10), $376,950USD, 01/01/2008 -- 05/31/2020
 
Novel Sulindac Derivatives for Colon Cancer Chemoprevention
PIAZZA, GARY A
National Institutes of Health (NIH), National Cancer Institute (NCI) (ID: 3R01CA131378-10S1), $22,725USD, 01/01/2008 -- 05/31/2020
 
Phosphodiesterase 10A, a novel target for lung cancer chemoprevention
PIAZZA, GARY A
National Institutes of Health (NIH), National Cancer Institute (NCI) (ID: 5R01CA197147-03), $346,556USD, 07/15/2016 -- 06/30/2021
2017
Novel Sulindac Derivatives for Colon Cancer Chemoprevention
PIAZZA, GARY A
National Institutes of Health (NIH), National Cancer Institute (NCI) (ID: 5R01CA131378-09), $376,950USD, 01/01/2008 -- 05/31/2020
 
Novel Sulindac Derivatives for Colon Cancer Chemoprevention
PIAZZA, GARY A
National Institutes of Health (NIH), National Cancer Institute (NCI) (ID: 3R01CA131378-09S1), $151,500USD, 01/01/2008 -- 05/31/2020
 
Phosphodiesterase 10A, a novel target for lung cancer chemoprevention
PIAZZA, GARY A
National Institutes of Health (NIH), National Cancer Institute (NCI) (ID: 5R01CA197147-02), $346,556USD, 07/15/2016 -- 06/30/2021
 
Phosphodiesterase 5: A Novel Target and Inhibitor for Breast Cancer Chemopreventi
PIAZZA, GARY A
National Institutes of Health (NIH), National Cancer Institute (NCI) (ID: 5R01CA155638-06), $385,363USD, 08/16/2012 -- 05/31/2019
2016
Novel Ras inhibitor prodrug for colorectal cancer
CANZONERI, JOSHUA and PIAZZA, GARY A
National Institutes of Health (NIH), National Cancer Institute (NCI) (ID: 1R43CA206807-01), $300,000USD, 08/01/2016 -- 07/31/2017
 
Novel Sulindac Derivatives for Colon Cancer Chemoprevention
PIAZZA, GARY A
National Institutes of Health (NIH), National Cancer Institute (NCI) (ID: 5R01CA131378-08), $376,950USD, 01/01/2008 -- 05/31/2020
 
PDE Inhibition by Sulindac Sulfide Amide Derivatives for Lung Cancer Chemoprevention
PIAZZA, GARY A and ZHU, BING
National Institutes of Health (NIH), National Cancer Institute (NCI) (ID: 5R21CA182941-02), $164,756USD, 02/01/2015 -- 01/31/2017
 
Phosphodiesterase 10A, a novel target for lung cancer chemoprevention
PIAZZA, GARY A
National Institutes of Health (NIH), National Cancer Institute (NCI) (ID: 1R01CA197147-01A1), $346,556USD, 07/15/2016 -- 06/30/2021
 
Phosphodiesterase 5: A Novel Target and Inhibitor for Breast Cancer Chemopreventi
PIAZZA, GARY A
National Institutes of Health (NIH), National Cancer Institute (NCI) (ID: 4R01CA155638-05), $1USD, 08/16/2012 -- 05/31/2018
 
Phosphodiesterase 5: A Novel Target and Inhibitor for Breast Cancer Chemopreventi
PIAZZA, GARY A
National Institutes of Health (NIH), National Cancer Institute (NCI) (ID: 3R01CA155638-05S1), $131,048USD, 08/16/2012 -- 05/31/2018
 
Selective anti-cancer activity of sulindac derivatives on KRAS mutant colon tumor cells by inducing ROS
PIAZZA, GARY A
National Institutes of Health (NIH), National Cancer Institute (NCI) (ID: 3R01CA131378-08S1), $128,775USD, 01/01/2008 -- 05/31/2020
2015
A novel phosphodiesterase isozyme target and class of inhibitors for lung cancer
CANZONERI, JOSHUA and PIAZZA, GARY A
National Institutes of Health (NIH), National Cancer Institute (NCI) (ID: 1R43CA189613-01A1), $224,879USD, 06/09/2015 -- 09/30/2016
 
Development of a novel sulindac amide for colorectal cancer chemoprevention
PIAZZA, GARY A
National Institutes of Health (NIH), National Cancer Institute (NCI) (ID: 5R01CA148817-06), $252,538USD, 08/01/2010 -- 05/31/2017